NCT00648817View on ClinicalTrials.gov

Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

December 31, 2007

Conditions
HIV Infections
Interventions
DRUG

Tenofovir Disoproxil Fumarate

Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)

DRUG

Tenofovir DF placebo

Tenofovir DF placebo tablet QD

Trial Locations (1)

SW10 9NH

Chelsea and Westminster Hospital, London

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00648817 - Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers | Biotech Hunter | Biotech Hunter